Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 1999

View Archived Issues

BioTransplant/MGH report extensively on xenotransplantation research at recent congress

Exelixis and Pharmacia & Upjohn expand collaboration

New data reported for Tamiflu as influenza treatment and prophylaxis

HepaVec acquires majority stake in MondoGen

D-Pharm completes toxicity testing of DP-b99 in preparation for phase I trials later this year

Cromafiban stands head and shoulders above others in its class

CombiChem reaches second milestone in collaboration with Teijin

Third quarter activities summarized by MedImmune

BMS reports R&D progress during the third quarter

Anti-H. pylori compound isolated from Acinetobacter at Takeda laboratories

Japanese researchers present new protein-tyrosine-phosphatase inhibitors

Dainippon discloses new compounds useful for the treatment or prophylaxis of liver disease

R&D highlights at Corixa during 3rd quarter

Vasopeptidase inhibitor steals the show at AHA

Kowa's new antiallergic agents inhibit IgE antibody production

Pyridone ACAT inhibitors in development at Sumitomo

Inhibition of telomerase as anticancer strategy under study at Chugai

Studies on absorption of ME-3229 in rat intestinal segments

Inhibitors of cytokine-mediated eosinophil survival as potential agents for asthma

News from AHA: Bayer presents promising new treatment for atherosclerosis

Aronex to lead further development of new liposomal platinum product

Teva licenses European rights to Parkinson's disease drugs to Lundbeck

Preclinical results indicate potential utility of JMR-193 in myocardial perfusion imaging

Specific inhibitors of cancer cell mitogenic pathways tested in combination with radiation

Novel photosensitizer from Miravant prevents postangioplasty restenosis in pig model

Small-molecule inhibitor of receptors of the EGF family may offer superior alternative to Herceptin

Nippon Zoki compound evaluated in diabetic patients with renal failure

Farnesyltransferase inhibitors + radiation synergistic in human tumors expressing mutated ras

Results of phase II trial of GA-EPO presented at ASN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...